Maurie Markman, MD

Maurie Markman, MD, addresses different treatment options, including checkpoint inhibitors, for patients with endometrial cancer.

Maurie Markman, MD, discusses how management and treatment strategies in ovarian cancer have influenced other cancers and will continue to do so.

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, discusses how the ovarian cancer treatment paradigm has evolved over the past 30 years.

Maurie Markman, MD, President of Medicine and Science at the Cancer Treatment Centers of America, discusses where he sees the field of ovarian cancer and other gynecologic cancers headed in the future, based on the research shared at the 2018 ASCO Annual Meeting.

Maurie Markman, MD, president of medicine and science, Cancer Treatment Centers of America, discusses valuable endpoints beyond overall survival (OS) that can be used in ovarian cancer clinical trials.

Maurie Markman, MD, president of medicine and science, Cancer Treatment Centers of America, discusses overall survival as an endpoint in ovarian cancer.

From the perspective of a patient and that patient’s family, it is completely understandable that the single most important goal of an antineoplastic strategy is to prolong survival and, if possible, produce a cure.

There is genuine excitement within the gynecologic cancer clinical and research communities for the potential role of PARP inhibitors in the management of ovarian cancer.

Maurie Markman, MD, president of Medicine and Science, Eastern Regional Medical Center, discusses immune targeting in ovarian cancer.

Maurie Markman, MD, president of Medicine and Science, Eastern Regional Medical Center, discusses when to perform a prophylactic bilateral oophorectomy on a patient who does not have ovarian cancer, but has a known BRCA mutation.

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, discusses the benefits and risks of performing a bilateral salpingo-oophorectomy as a treatment for patients with ovarian cancer.

Maurie Markman, MD, discusses characterizing tumor types in ovarian cancer and treating the malignancy with checkpoint inhibitors.

Maurie Markman, MD, president of Medicine and Science, Eastern Regional Medical Center, talks about use of PD-1 inhibitors in ovarian cancer and the lack of evidence pointing toward their functionality.

Maurie Markman, MD, discusses the role of molecular testing in gynecologic cancers.